GSK to Acquire Oncology Biotech Nuvalent for $10.6B in Cash
GSK has announced that it will acquire oncology biotech Nuvalent in a $10.6 billion cash transaction.
Nuvalent is developing targeted therapies for non-small cell lung cancer, including its lead candidates zidesamtinib and neladalkib, which are currently under FDA review.
Deal Overview
- $10.6 billion cash transaction
- Purchase price of $124 per share
- Lead candidates include zidesamtinib and neladalkib
- Focus on ROS1- or ALK-positive non-small cell lung cancer
- Both candidates are under FDA review, with decisions expected in 2026
Zidesamtinib and neladalkib are being developed as next-generation candidates designed with resistance after prior therapy, CNS penetration, and tolerability in mind. If approved, they would add new growth opportunities to GSK’s oncology portfolio.
In lung cancer, treatment selection is increasingly shaped by driver mutations. Beyond the target itself, activity against resistance mutations and central nervous system penetration are also becoming important points of differentiation.
Across oncology M&A, large pharma companies are not only looking for discovery platforms or early-stage technologies. Late-stage assets close to potential approval remain a key route to strengthening short- and mid-term pipelines.
Congratulations to both teams at GSK and Nuvalent.